OrthoPediatrics target raised to $33 on ‘excellent’ momentum at Piper Jaffray

Piper Jaffray analyst Matt O’Brien raised his price target for OrthoPediatrics to $33 from $30 saying the company’s business momentum is “excellent” following its beat and raise Q2. OrthoPediatrics remains a unique name within orthopedics that investors should own, O’Brien tells investors in a research note. He keeps an Overweight rating on the name.

https://bit.ly/2MkVixf